profit from every $100 of sales.
$0$100
NRx Pharmaceuticals
$2.19-3.95% today
-15.4% in 1 year
1-year low $1.681-year high $4.62
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What NRx Pharmaceuticals sold, what it kept, and what it did with the cash.
Sales went from $0 in 2022 to $1.23 million in 2025, with -$28.6 million of profit last year.
SalesProfit
NRx Pharmaceuticals vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| NRx Pharmaceuticals | No profit yet | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads NRx Pharmaceuticals's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 0 | 1 | |
| – | – | 0 | 1 | |
| -44 | -28 | -19 | -16 | |
| -40 | -30 | -25 | -28 | |
| -40 | -30 | -25 | -29 | |
| -6.10 | -3.98 | -2.36 | -1.34 | |
| – | – | – | 58.8% | |
| – | – | – | -1,324.4% | |
| – | – | – | -2,336.5% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 26 | 7 | 4 | 13 |
| Cash | 20 | 5 | 1 | 8 |
| Total debt | 11 | 9 | 7 | 1 |
| Total liabilities | 18 | 19 | 27 | 29 |
| 7 | -12 | -23 | -16 | |
| 7 | 8 | 11 | 21 | |
| -175.1% | – | – | – | |
| -536.6% | 257.0% | 108.2% | 179.6% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -40 | -22 | -11 | -14 | |
| 0 | 0 | – | – | |
| -40 | -22 | -11 | -14 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 4 | 0 | 0 | 0 |
Valuation
- –
- 2.9×
- –
- -7.5×
- 77.4×
- –
- –
- -14.9%
- -30.2%
- 0.0%
Profitability
- 58.8%
- -1,324.4%
- -2,336.5%
- -1,340.4%
- 133.4%
- 170.4%
- 107.7%
- -206.2%
- 129.5%
- 186.8%
Growth
- –
- –
- −32.7%
- –
- −17.8%
Financial health
- -0.3×
- -0.07
- 7.8%
- -19.0×
- 0.29
- 0.29
- 0.19
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 1%of 946
Bottom 7%of 986
What analysts expect
- Average price target
- $2.00
- Range
- $2.00 – $2.00
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 15, 2026 | -0.04 | -0.05 | +20.0% |
| Mar 23, 2026 | 0.19 | -0.09 | +311.1% |
| Nov 14, 2025 | -0.18 | -0.11 | −63.6% |
| May 15, 2025 | -0.34 | -0.30 | −13.3% |
| Mar 14, 2025 | -0.30 | -0.20 | −50.0% |
| Nov 14, 2024 | -0.15 | -0.81 | +81.5% |
| Aug 14, 2024 | -0.75 | -0.81 | +7.4% |
| May 14, 2024 | -0.74 | -0.55 | −34.5% |
News
Reviva Pharmaceuticals GAAP EPS of -$0.17 beats by $0.23Seeking Alpha · Nov 13, 2026Eupraxia Pharmaceuticals reports Q3 resultsSeeking Alpha · Nov 11, 2026Ionis Pharmaceuticals Q3 2026 Earnings PreviewSeeking Alpha · Nov 6, 2026ANI Pharmaceuticals beats top-line and bottom-line estimates; narrows FY26 outlookSeeking Alpha · Nov 5, 2026Vertex Pharmaceuticals Q3 2026 Earnings PreviewSeeking Alpha · Nov 1, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
4/6Passes 4 of 6. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
48No pass
Benjamin Graham
4No pass
Philip Fisher
74Pass
Peter Lynch
–Not enough data
Joel Greenblatt
71Pass
Charlie Munger
74Pass
Terry Smith
65Pass
Questions about NRx Pharmaceuticals
Is NRx Pharmaceuticals a good stock to buy?
A business with weak numbers that is not profitable yet. 4 of the 6 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the NRx Pharmaceuticals AI analysis
What does NRx Pharmaceuticals do?
NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It is in Biotechnology.
Does NRx Pharmaceuticals pay a dividend?
No. NRx Pharmaceuticals does not pay a dividend at the moment.
Is NRx Pharmaceuticals stock halal?
Yes. NRx Pharmaceuticals passes our halal screen: its business is permitted and its debt is 0.6% of its market value, under the 30% limit. How we check
How has NRx Pharmaceuticals stock done over the past year?
Down 15.4% over the past twelve months, to $2.19. It traded between $1.68 and $4.62 and is 52.6% below its high.
Who are NRx Pharmaceuticals's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with NRx Pharmaceuticals's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.